Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Limptar N is a small molecule drug containing quinine sulfate, a natural alkaloid derived from cinchona bark. It is primarily indicated for the therapy and prophylaxis of skeletal muscle cramps, particularly nocturnal leg cramps in adults. The drug works by reducing excitability at the skeletal muscle and neuromuscular junction, which decreases the responsiveness of muscle cells to stimuli and increases the muscle's refractory period. Developed by Cassella-med, Limptar N is available over-the-counter in German pharmacies. Beyond its approved use for muscle cramps, it has been investigated in Phase 3 clinical trials in Germany for the treatment of fibromyalgia, evaluating its efficacy in reducing pain and tenderness using assessments such as the Fibromyalgia Impact Questionnaire.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on quinine sulfate.